To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis
Launched by UCB PHARMA · Sep 4, 2007
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female, 18 to 60 years old, inclusive
- • two-year history of allergic rhinitis due to tree, grass or weed pollen
- • sufficient histamine-dependent symptoms of rhinitis during the selection week (T5SS ≥ 5)
- Exclusion Criteria:
- • An ear, nose or throat (ENT) infection
- • asthma requiring daily drug therapy other than ß2 inhaled agonists taken prn
- • atopic dermatitis or urticaria requiring an antihistamine or corticosteroid treatment
- • an associated ENT disease
- • use of decongestants
- • nasal or ocular topical treatment
About Ucb Pharma
UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
UCB Clinical Trial Call Center
Study Director
UCB Pharma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials